Twist Bioscience (TWST) Gains from Investment Securities (2017 - 2026)

Twist Bioscience has disclosed Gains from Investment Securities across 10 years of filings, most recently posting -$24.8 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 825633.33% year-over-year to -$24.8 million; the TTM figure through Mar 2026 stood at $1000.0 (up 100.08% YoY), while the FY2024 annual figure was -$994000.0, up 83.19% from the prior year.
• Gains from Investment Securities eased to -$24.8 million in Q1 2026, from $24.8 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for TWST reached as high as $24.8 million in Q4 2025 and fell as low as -$24.8 million in Q1 2026.
• The 5-year median for Gains from Investment Securities is -$444000.0 (2022), against an average of -$1.4 million.
• Annual changes were most pronounced in 2025 — Gains from Investment Securities soared 825666.67% — and 2026, when it sank 825633.33%.
• A 5-year view of Gains from Investment Securities shows it stood at $52000.0 in 2022, then sank by 676.92% to -$300000.0 in 2023, then soared by 101.0% to $3000.0 in 2024, then soared by 825666.67% to $24.8 million in 2025, then tumbled by 200.0% to -$24.8 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$24.8 million, $24.8 million, and -$603000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.